Malta Enterprise signs letter of intent with cannabis firm EMMAC

Malta Enterprise signed a letter of intent with European independent medical cannabis company EMMAC, under which the latter would be eligible to open a turnkey GMP facility in Malta, according to a press statement issued at the beginning of February.

The letter of intent was granted to EMMAC under terms of the Production of Cannabis for Medicinal Use Act, 2018, Chapter 578 of the Laws of Malta. The letter of intent is preliminary approval for the issuance of a full license — covering cultivation, production, importation and exportation — under the terms of the Production of Cannabis for Medicinal Use Act, 2018, according to the press statement.

EMMAC aims the turnkey GMP facility in Malta to be the group’s importation, exportation, testing and distribution hub for Europe and other international markets.

“We are delighted to have had such strong support from the Maltese Government and relevant public and regulatory authorities,” says Antonio Costanzo, CEO of EMMAC. “As the demand for premium quality medical cannabis continues to grow, our facility in Malta will form a critical part of EMMAC’s unique European infrastructure as our group import and distribution hub,” Mr Constanzo adds.

European medical cannabis company EMMAC Life Sciences Plc says it is committed to working to join together the latest science and research with cutting-edge cultivation, extraction and production. The firm has supply and distribution partnerships throughout Europe.